Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Recombinant Adenoviral p53 Human Gene in Recurrent Ovarian Cancer
NCT02435186Phase 2Unknown
- Sponsor
- Shenzhen SiBiono GeneTech
- Start
- Jun 2015
- Primary completion
- Aug 2018
- Modality
- Gene Editing, Gene Silencing, Viral Vectors
- Countries
- 1
01
Overview
A Phase 2 trial of recombinant human p53 adenovirus injection in ovarian epithelial cancer, fallopian tube cancer (PFTC), primary peritoneal cancer (PPC), sponsored by Shenzhen SiBiono GeneTech. Status: unknown.
02
Drugs
recombinant human p53 adenovirus injection
03
Conditions
ovarian epithelial cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NCT02435186.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02435186.